Why the study?
To evaluate the impact of a quality improvement initiative featuring a dedicated Adult Congenital Anesthesia and ICU team and factor concentrates on perioperative outcomes in adult congenital cardiac surgery.
Does a quality improvement initiative with a dedicated anesthesia team reduce in-hospital mortality in adult congenital heart disease patients undergoing surgery?
Does a quality improvement initiative with a dedicated anesthesia team reduce in-hospital mortality in adult congenital heart disease patients undergoing surgery?
A quality improvement initiative with a dedicated anesthesia and ICU team significantly reduced in-hospital and 1-year mortality in adult congenital cardiac surgery patients.
Mortality reduction after QI in adult congenital surgery may support specialized teams; leaves open whether dedicated anesthesia or factor concentrates drove benefit in this observational study.
Objectives A quality improvement initiative was introduced to the adult congenital cardiac surgery program at Toronto General Hospital in January 2016. A dedicated Adult Congenital Anesthesia and intensive care unit team was introduced within the cardiac group. The use of factor concentrates was introduced. The study compares perioperative mortality, adverse events, and transfusion burden before and after this process change. Methods We performed a retrospective analysis of all adult congenital cardiac surgeries from January 2004 to July 2019. Two groups were analyzed: patients undergoing operation before and after 2016. The primary outcome was in-hospital mortality. One-year mortality and prevalence of key morbidities were analyzed as secondary outcomes. A separate analysis looked at patients who had and had not attended an anesthesia-led preassessment clinic. Results In-hospital mortality was significantly reduced in patients undergoing operation after 2016 (1.1% vs 4.3%, P = .003) despite a higher risk profile. One-year mortality (1.3% vs 5.8%, P = .003) and ventilation times (5.5 hours [3.4-13.0] vs 6.3 hours [4.2-16.2], P = .001) were also reduced. The incidence of stroke and renal failure was similar between groups. Blood product exposure was comparable, but the incidence of chest reopening decreased (1.8% vs 4.8%, P = .022), despite more patients with multiple previous chest wall incisions, on anticoagulation, and with more complex cardiac anatomy. There were no significant outcome differences between those who did or did not attend the preassessment clinic. Conclusions Both in-hospital and 1-year mortality were significantly reduced after the introduction of a quality improvement program, despite a higher risk profile. Blood product exposure remained unchanged, but there were less chest reopenings.
No takes yet. Share an insight, caveat, or question.
Walsh et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: